Premium listings
  • 3rd International Conference on Transcriptomics

    3rd International Conference on Transcriptomics

    Life Sciences Bangkok (Bangkok) March 13, 2017 Check with publisher

    Conference Series has been instrumental in conducting international Biochemistry meetings for seven years, and very excited to expand Europe, America and Asia Pacific continents. Previous meetings were held in major cities like Philadelphia, Orlando ...

  • Developing drugs for the treatment of neurodegenerative diseases

    Developing drugs for the treatment of neurodegenerative diseases

    PhD Studentships Liverpool December 3, 2016 Check with publisher

    Ageing is arguably the major biomedical challenge of the 21st century with the incidence of age-related diseases, and neurodegenerative diseases in particular, expected to increase dramatically in the coming decades. In model organisms, the process o...

  • DrugAge database of compounds that increase lifespan

    DrugAge database of compounds that increase lifespan

    Biomedical Sciences Liverpool August 24, 2015 Check with publisher

    We're starting a new database of drugs and compounds (including natural products) with anti-ageing properties that extend longevity in model organisms. The database will be called DrugAge, and although we have some data already, we are looking for da...

Listings
  • Anti-CR2 (THB-5)-SPP-DM1 ADC

    Anti-CR2 (THB-5)-SPP-DM1 ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CR2 monoclonal antibody (THB-5) conjugated via a SPP linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cel...

  • Products Used in Early Phase IND Studies

    Products Used in Early Phase IND Studies

    Quality Control, Safety & Security Fremont (California) November 27, 2017 Free

    Overview: How it may be integrated with the recommendations of the guidance documents on CMC requirements. Areas Covered in the Session: Discussion of the elements found in the guidance document for Phase 1 material What to do at really early stages ...

  • To Facilitate a Closed-Loop Problem Resolution System

    To Facilitate a Closed-Loop Problem Resolution System

    Training and Teaching Fremont (California) November 27, 2017 150.00 Dollar US$

    Overview: Defined Failure Investigation and Root Cause Analysis is a major tool in product complaint, non-conformance, and OOS failure investigations. Why should you Attend: Expectations for meaningful CAPA, supported by results-driven Failure Invest...

  • Anti-cKIT (9P3)-SPDB-DM4 ADC

    Anti-cKIT (9P3)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-cKIT monoclonal antibody (9P3) conjugated via a SPDB linker to DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cel...

  • Anti-CEACAM5 (clone huMAb2-4)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone huMAb2-4)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone huMAb2-4) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis...

  • Anti-CEACAM5 (clone huMAb2-3)-sulfoSPDB-DM4 ADC

    Anti-CEACAM5 (clone huMAb2-3)-sulfoSPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone huMAb2-3) conjugated via a sulfoSPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocy...

  • Anti-CEACAM5 (clone huMAb2-3)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone huMAb2-3)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone huMAb2-3) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis...

  • Anti-CEACAM5 (clone huMAb2-1)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone huMAb2-1)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone huMAb2-1) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis...

  • Anti-CEACAM5 (clone huMAb2-2)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone huMAb2-2)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone huMAb2-2) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis...

  • Anti-CEACAM5 (clone chMAb1)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone chMAb1)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone chMAb1) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. ...

  • Anti-CEACAM5 (clone chMAb5)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone chMAb5)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone chMAb5) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. ...

  • Anti-CEACAM5 (clone chMAb4)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone chMAb4)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone chMAb4) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. ...